Overview
Davide Crucitti practices practicing medicine in Santiago De Compostela, Spain.
His clinical expertise encompasses Myelodysplastic Syndrome (MDS), Myelofibrosis, and Leukemia.
He is actively involved in clinical research, co-authoring 9 peer reviewed articles.
Gender
Locations
Clinical Research
Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.
Frequently Asked Questions about Davide Crucitti
Is Davide Crucitti a top-rated expert for Myelodysplastic Syndrome (MDS)?
MediFind is an objective health platform that identifies experts based on real-world data. Davide Crucitti is classified as an Experienced expert for Myelodysplastic Syndrome (MDS), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.
Does Davide Crucitti participate in research or clinical trials?
Yes. Davide Crucitti has published 9 articles and abstracts on conditions like Myelodysplastic Syndrome (MDS). You can view a list of Davide Crucitti's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.
Areas of Expertise
MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.
Learn more about MediFind’s expert tiers
- Experienced
- LeukemiaMr. Crucitti isExperienced. Learn about Leukemia.
- Myelodysplastic Syndrome (MDS)Mr. Crucitti isExperienced. Learn about Myelodysplastic Syndrome (MDS).
- MyelofibrosisMr. Crucitti isExperienced. Learn about Myelofibrosis.